Delaware | 001-13111 | 94-3229046 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Title of each class: | Trading Symbol(s): | Name of each exchange on which registered: | ||
Common Stock, $0.0001 par value | ASRT | The Nasdaq Stock Market LLC |
Item 2.02 | Results of Operations and Financial Condition. |
Item 9.01 | Financial Statements and Exhibits. | |||
(d) | Exhibits | |||
99.1 |
ASSERTIO THERAPEUTICS, INC. | ||
Date: August 7, 2019 | By: | /s/ Daniel A. Peisert |
Daniel A. Peisert | ||
Senior Vice President and Chief Financial Officer |
Second Quarter 2019 | ||
(in millions, except earnings per share) | GAAP | Non-GAAP(1) |
Total Revenues | $57.2 | $59.3 |
Net Income/(Loss) | $(13.6) | $18.5 |
Earnings/(Loss) Per Share | $(0.21) | $0.25 |
Adjusted EBITDA | - | $36.7 |
• | Neurology Franchise Net Sales: Gralise net sales in the second quarter were $17.8 million, primarily due to favorable year-over-year gross to net reflecting payor mix. In August, the Company executed an agreement that provides expanded access for Gralise through new coverage with one of the top three Medicare Part-D insurers, representing more than 6 million lives. Obtaining expanded Medicare Part-D access is important for Gralise as a majority of patients with postherpetic neuralgia are more than 65 years old. In the second quarter, Zipsor net sales were $1.5 million, adversely impacted by short-dated product sales returns; however, underlying prescription demand for Zipsor continues to grow double digits year-over-year. CAMBIA net sales in the second quarter were $6.8 million, primarily due to unfavorable year-over-year gross to net reflecting payor mix. Underlying prescription demand for CAMBIA increased mid single digits year-over-year. |
• | Debt Reduction and Cash Position: As of August 7, 2019, the Company has made scheduled principal repayments of $100.0 million in 2019, reducing the Company’s senior secured debt to $182.5 million. The Company will make an additional $20 million principal payment before year end, reducing senior secured debt to $162.5 million. As of June 30, 2019, the Company had cash and cash equivalents and short-term investments of $75.5 million. |
• | One-Year Anniversary of Headquarters Relocation, Reincorporation and Name Change to Assertio Therapeutics, Inc.: Approximately one year ago, the Company completed its reincorporation from California to Delaware and changed its name from “Depomed, Inc.” to “Assertio Therapeutics, Inc.” In connection with the reincorporation and name change, the Company’s common stock began trading under a new ticker symbol “ASRT.” The Company also completed the relocation of its corporate headquarters from Newark, CA, to Lake Forest, IL. |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
Product sales, net | |||||||||||||||
Gralise | $ | 17,800 | $ | 13,815 | $ | 31,078 | $ | 28,642 | |||||||
CAMBIA | 6,758 | 8,089 | 15,566 | 14,505 | |||||||||||
Zipsor | 1,524 | 3,988 | 5,755 | 8,734 | |||||||||||
Total neurology product sales, net | 26,082 | 25,892 | 52,399 | 51,881 | |||||||||||
NUCYNTA products | (163 | ) | 626 | (101 | ) | 18,771 | |||||||||
Lazanda | 18 | 320 | 89 | 540 | |||||||||||
Total product sales, net | 25,937 | 26,838 | 52,387 | 71,192 | |||||||||||
Commercialization agreement: | |||||||||||||||
Commercialization rights and facilitation services | 31,003 | 31,179 | 61,859 | 59,274 | |||||||||||
Revenue from transfer of inventory | — | — | — | 55,705 | |||||||||||
Royalties and Milestone Revenue | 263 | 5,257 | 886 | 5,507 | |||||||||||
Total revenues | $ | 57,203 | $ | 63,274 | $ | 115,132 | $ | 191,678 |
Prior 2019 Guidance | Current 2019 Guidance | |
Neurology Franchise Net Sales | Low to Mid-Single Digit Growth | Low-Single Digit Growth |
GAAP Net Loss(1) | ($68) to ($58) million | ($68) to ($58) million |
Non-GAAP Adjusted EBITDA(1)(2) | $118 to $128 million | $118 to $128 million |
• | From the Assertio website: http://investor.assertiotx.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. |
• | By telephone: Participants can access the call by dialing (877) 550-3745 (United States) or (281) 973-6277 (International) referencing Conference ID 7769879. |
• | By replay: A replay of the webcast will be located under the Investor Relations section of Assertio’s website approximately two hours after the conclusion of the live call. |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
Revenues: | |||||||||||||||
Product sales, net | $ | 25,937 | $ | 26,838 | $ | 52,387 | $ | 71,192 | |||||||
Commercialization agreement, net | 31,003 | 31,179 | 61,859 | 114,979 | |||||||||||
Royalties and milestones | 263 | 5,257 | 886 | 5,507 | |||||||||||
Total revenues | 57,203 | 63,274 | 115,132 | 191,678 | |||||||||||
Costs and expenses: | |||||||||||||||
Cost of sales (excluding amortization of intangible assets) | 2,124 | 2,753 | 4,699 | 14,797 | |||||||||||
Research and development expenses | 1,263 | 2,180 | 3,056 | 3,708 | |||||||||||
Selling, general and administrative expenses | 24,755 | 31,308 | 49,800 | 60,341 | |||||||||||
Amortization of intangible assets | 25,443 | 25,444 | 50,887 | 50,888 | |||||||||||
Restructuring charges | — | 5,814 | — | 14,831 | |||||||||||
Total costs and expenses | 53,585 | 67,499 | 108,442 | 144,565 | |||||||||||
Income (loss) from operations | 3,618 | (4,225 | ) | 6,690 | 47,113 | ||||||||||
Other (expense) income: | |||||||||||||||
Interest expense | (14,842 | ) | (17,010 | ) | (31,396 | ) | (35,078 | ) | |||||||
Other (expense) income, net | (1,240 | ) | 67 | (1,849 | ) | 296 | |||||||||
Total other expense | (16,082 | ) | (16,943 | ) | (33,245 | ) | (34,782 | ) | |||||||
Net (loss) income before income taxes | (12,464 | ) | (21,168 | ) | (26,555 | ) | 12,331 | ||||||||
Income taxes (expense) benefit | (1,141 | ) | 120 | (1,351 | ) | 445 | |||||||||
Net (loss) income | $ | (13,605 | ) | $ | (21,048 | ) | $ | (27,906 | ) | $ | 12,776 | ||||
Basic net (loss) income per share | (0.21 | ) | (0.33 | ) | (0.43 | ) | 0.20 | ||||||||
Diluted net (loss) income per share | (0.21 | ) | (0.33 | ) | (0.43 | ) | 0.20 | ||||||||
Shares used in computing basic net (loss) income per share | 64,480 | 63,719 | 64,405 | 63,611 | |||||||||||
Shares used in computing diluted net (loss) income per share | 64,480 | 63,719 | 64,405 | 64,107 |
June 30, 2019 | December 31, 2018 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 68,348 | $ | 110,949 | |||
Short-term investments | 7,114 | — | |||||
Accounts receivable, net | 34,311 | 37,211 | |||||
Inventories, net | 3,005 | 3,396 | |||||
Prepaid and other current assets | 26,231 | 56,551 | |||||
Total current assets | 139,009 | 208,107 | |||||
Property and equipment, net | 13,050 | 13,064 | |||||
Intangible assets, net | 641,212 | 692,099 | |||||
Investments | 8,589 | 11,784 | |||||
Other long-term assets | 11,014 | 7,812 | |||||
Total assets | $ | 812,874 | $ | 932,866 | |||
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 2,188 | $ | 6,138 | |||
Accrued rebates, returns and discounts | 63,808 | 75,759 | |||||
Accrued liabilities | 19,648 | 31,361 | |||||
Current portion of Senior Notes | 80,000 | 120,000 | |||||
Interest payable | 9,194 | 11,645 | |||||
Other current liabilities | 2,100 | 1,133 | |||||
Total current liabilities | 176,938 | 246,036 | |||||
Contingent consideration liability | 953 | 1,038 | |||||
Senior Notes | 117,527 | 158,309 | |||||
Convertible Notes | 297,550 | 287,798 | |||||
Other long-term liabilities | 22,467 | 19,350 | |||||
Total liabilities | 615,435 | 712,531 | |||||
Commitments and contingencies | |||||||
Shareholders’ equity: | |||||||
Common stock | 6 | 6 | |||||
Additional paid-in capital | 407,944 | 402,934 | |||||
Accumulated deficit | (210,506 | ) | (182,600 | ) | |||
Accumulated other comprehensive loss | (5 | ) | (5 | ) | |||
Total shareholders’ equity | 197,439 | 220,335 | |||||
Total liabilities and shareholders' equity | $ | 812,874 | $ | 932,866 |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
GAAP net (loss)/income | $ | (13,605 | ) | $ | (21,048 | ) | $ | (27,906 | ) | $ | 12,776 | ||||
Commercialization agreement revenues (1) | 1,933 | 3,198 | 3,863 | (49,288 | ) | ||||||||||
Commercialization agreement cost of sales (2) | — | — | — | 6,200 | |||||||||||
NUCYNTA sales reserve (3) | — | — | — | (10,711 | ) | ||||||||||
NUCYNTA and Lazanda revenue reserves (4) | 145 | (946 | ) | 12 | (1,166 | ) | |||||||||
Expenses for opioid-related litigation, investigations and regulations (5) | 2,350 | 2,220 | 4,850 | 3,047 | |||||||||||
Intangible amortization related to product acquisitions | 25,443 | 25,444 | 50,887 | 50,888 | |||||||||||
Contingent consideration related to product acquisitions | (142 | ) | (260 | ) | (142 | ) | (462 | ) | |||||||
Stock-based compensation | 2,634 | 2,970 | 5,336 | 4,946 | |||||||||||
Interest and other income | (172 | ) | (70 | ) | (673 | ) | (164 | ) | |||||||
Interest expense | 14,842 | 17,010 | 31,396 | 35,078 | |||||||||||
Depreciation | 279 | 1,454 | 616 | 2,929 | |||||||||||
Income taxes (expense) benefit | 1,141 | (120 | ) | 1,351 | (445 | ) | |||||||||
Restructuring and related costs (6) | — | 6,974 | — | 15,299 | |||||||||||
Other costs | — | (31 | ) | — | 178 | ||||||||||
Fair value for warrants | 1,848 | — | 3,477 | — | |||||||||||
Non-GAAP adjusted EBITDA | $ | 36,696 | $ | 36,795 | $ | 73,067 | $ | 69,105 |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
GAAP net (loss)/income | $ | (13,605 | ) | $ | (21,048 | ) | $ | (27,906 | ) | $ | 12,776 | ||||
Commercialization agreement revenues (1) | 1,933 | 3,198 | 3,863 | (49,288 | ) | ||||||||||
Commercialization agreement cost of sales (2) | — | — | — | 6,200 | |||||||||||
Nucynta sales reserve (3) | — | — | — | (10,711 | ) | ||||||||||
Non-cash interest expense on debt | 6,056 | 5,390 | 12,220 | 10,808 | |||||||||||
Nucynta and Lazanda revenue reserves (4) | 145 | (946 | ) | 12 | (1,166 | ) | |||||||||
Expenses for opioid-related litigation, investigations and regulations (5) | 2,350 | 2,220 | 4,850 | 3,047 | |||||||||||
Intangible amortization related to product acquisitions | 25,443 | 25,444 | 50,887 | 50,888 | |||||||||||
Contingent consideration related to product acquisitions | (142 | ) | (260 | ) | (142 | ) | (462 | ) | |||||||
Stock-based compensation | 2,634 | 2,970 | 5,336 | 4,946 | |||||||||||
Restructuring and related costs (6) | — | 6,974 | — | 15,304 | |||||||||||
Other costs | — | (31 | ) | (332 | ) | 178 | |||||||||
Fair value for warrants | 1,848 | — | 3,477 | — | |||||||||||
Income tax effect of non-GAAP adjustments (7) | (8,124 | ) | (9,067 | ) | (16,163 | ) | (5,623 | ) | |||||||
Non-GAAP adjusted earnings | $ | 18,538 | $ | 14,844 | $ | 36,102 | $ | 36,897 | |||||||
Add interest expense of convertible debt, net of tax (8) | 1,703 | 1,703 | 3,406 | 3,406 | |||||||||||
Numerator | $ | 20,241 | $ | 16,547 | $ | 39,508 | $ | 40,303 | |||||||
Shares used in calculation (8) | 82,411 | 82,201 | 82,336 | 82,039 | |||||||||||
Non-GAAP adjusted diluted earnings per share | $ | 0.25 | $ | 0.20 | $ | 0.48 | $ | 0.49 |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
GAAP net (loss)/income per share | $ | (0.21 | ) | $ | (0.33 | ) | $ | (0.43 | ) | $ | 0.20 | ||||
Conversion from basic shares to diluted shares | 0.05 | 0.07 | 0.09 | (0.05 | ) | ||||||||||
Commercialization agreement revenues | 0.02 | 0.04 | 0.05 | (0.60 | ) | ||||||||||
Commercialization agreement cost of sales | — | — | — | 0.08 | |||||||||||
NUCYNTA sales reserve | — | — | — | (0.13 | ) | ||||||||||
Non-cash interest expense on debt | 0.07 | 0.06 | 0.15 | 0.14 | |||||||||||
NUCYNTA and Lazanda revenue reserves | — | (0.01 | ) | — | (0.01 | ) | |||||||||
Expenses for opioid-related litigation, investigations and regulations | 0.03 | 0.03 | 0.06 | 0.04 | |||||||||||
Intangible amortization related to product acquisitions | 0.31 | 0.31 | 0.62 | 0.62 | |||||||||||
Contingent consideration related to product acquisitions | — | — | — | (0.01 | ) | ||||||||||
Stock based compensation | 0.03 | 0.04 | 0.06 | 0.06 | |||||||||||
Restructuring and related costs | — | 0.08 | — | 0.18 | |||||||||||
Change in fair value of warrants | 0.02 | — | 0.04 | — | |||||||||||
Income tax effect of non-GAAP adjustments | (0.10 | ) | (0.11 | ) | (0.20 | ) | (0.07 | ) | |||||||
Add interest expense of convertible debt, net of tax | 0.03 | 0.02 | 0.04 | 0.04 | |||||||||||
Non-GAAP adjusted diluted earnings per share | $ | 0.25 | $ | 0.20 | $ | 0.48 | $ | 0.49 |
Commercialization agreement revenues | Product Sales | Royalties and milestones | Cost of sales | Research and development expense | Selling, general and administrative expense | Amortization of intangible assets | Interest expense | Other (Expense) Income, Net | Income taxes (expense) benefit | |||||||||||||||||||||||||||||||
GAAP as reported | $ | 31,003 | $ | 25,937 | $ | 263 | $ | 2,124 | $ | 1,263 | $ | 24,755 | $ | 25,443 | $ | (14,842 | ) | $ | (1,240 | ) | $ | (1,141 | ) | |||||||||||||||||
Commercialization agreement revenues and cost of sales | 1,933 | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
NUCYNTA sales reserve | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Non-cash interest expense on debt | — | — | — | — | — | — | — | 6,056 | — | — | ||||||||||||||||||||||||||||||
NUCYNTA and Lazanda revenue reserves | — | 145 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Expenses for opioid-related litigation, investigations and regulations | — | — | — | — | — | (2,350 | ) | — | — | — | — | |||||||||||||||||||||||||||||
Intangible amortization related to product acquisitions | — | — | — | — | — | — | (25,443 | ) | — | — | — | |||||||||||||||||||||||||||||
Contingent consideration related to product acquisitions | — | — | — | — | — | 142 | — | — | — | — | ||||||||||||||||||||||||||||||
Stock based compensation | — | — | — | (50 | ) | (76 | ) | (2,508 | ) | — | — | — | — | |||||||||||||||||||||||||||
Change in fair value of warrants | — | — | — | — | — | — | — | — | 1,848 | — | ||||||||||||||||||||||||||||||
Other costs | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Income tax effect of non-GAAP adjustments | — | — | — | — | — | — | — | — | — | (8,124 | ) | |||||||||||||||||||||||||||||
Non-GAAP adjusted | $ | 32,936 | $ | 26,082 | $ | 263 | $ | 2,074 | $ | 1,187 | $ | 20,039 | $ | — | $ | (8,786 | ) | $ | 608 | $ | (9,265 | ) |
Commercialization agreement revenues | Product Sales | Royalties and milestones | Cost of sales | Research and development expense | Selling, general and administrative expense | Amortization of intangible assets | Interest expense | Other (Expense) Income, Net | Income taxes (expense) benefit | |||||||||||||||||||||||||||||||
GAAP as reported | $ | 61,859 | $ | 52,387 | $ | 886 | $ | 4,699 | $ | 3,056 | $ | 49,800 | $ | 50,887 | $ | (31,396 | ) | $ | (1,849 | ) | $ | (1,351 | ) | |||||||||||||||||
Commercialization agreement revenues and cost of sales | 3,863 | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Non-cash interest expense on debt | — | — | — | — | — | — | — | 12,220 | — | — | ||||||||||||||||||||||||||||||
NUCYNTA and Lazanda revenue reserves | — | 12 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Expenses for opioid-related litigation, investigations and regulations | — | — | — | — | — | (4,850 | ) | — | — | — | — | |||||||||||||||||||||||||||||
Intangible amortization related to product acquisitions | — | — | — | — | — | — | (50,887 | ) | — | — | — | |||||||||||||||||||||||||||||
Contingent consideration related to product acquisitions | — | — | — | — | — | 142 | — | — | — | — | ||||||||||||||||||||||||||||||
Stock based compensation | — | — | — | (50 | ) | (349 | ) | (4,937 | ) | — | — | — | — | |||||||||||||||||||||||||||
Change in fair value of warrants | — | — | — | — | — | — | — | — | 3,477 | — | ||||||||||||||||||||||||||||||
Other costs | — | — | — | — | — | — | — | — | (332 | ) | — | |||||||||||||||||||||||||||||
Income tax effect of non-GAAP adjustments | — | — | — | — | — | — | — | — | — | (16,163 | ) | |||||||||||||||||||||||||||||
Non-GAAP adjusted | $ | 65,722 | $ | 52,399 | $ | 886 | $ | 4,649 | $ | 2,707 | $ | 40,155 | $ | — | $ | (19,176 | ) | $ | 1,296 | $ | (17,514 | ) |
Commercialization agreement revenues | Product Sales | Royalties and milestones | Cost of sales | Research and development expense | Selling, general and administrative expense | Restructuring Charges | Amortization of intangible assets | Interest expense | Other (Expense) Income, Net | Income taxes (expense) benefit | ||||||||||||||||||||||||||||||||||
GAAP as reported | $ | 31,179 | $ | 26,838 | $ | 5,257 | $ | 2,753 | $ | 2,180 | $ | 31,308 | $ | 5,814 | $ | 25,444 | $ | (17,010 | ) | $ | 67 | $ | 120 | |||||||||||||||||||||
Commercialization agreement revenues and cost of sales | 3,198 | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
Non-cash interest expense on debt | — | — | — | — | — | — | — | — | 5,390 | — | — | |||||||||||||||||||||||||||||||||
NUCYNTA and Lazanda revenue reserves | — | (946 | ) | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Expenses for opioid-related litigation, investigations and regulations | — | — | — | — | — | (2,220 | ) | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Intangible amortization related to product acquisitions | — | — | — | — | — | — | — | (25,444 | ) | — | — | — | ||||||||||||||||||||||||||||||||
Contingent consideration related to product acquisitions | — | — | — | — | — | 260 | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Stock based compensation | — | — | — | (16 | ) | (14 | ) | (2,940 | ) | — | — | — | — | — | ||||||||||||||||||||||||||||||
Restructuring and other costs | — | — | — | — | — | 31 | (6,974 | ) | — | — | — | — | ||||||||||||||||||||||||||||||||
Income tax effect of non-GAAP adjustments | — | — | — | — | — | — | — | — | — | — | (9,067 | ) | ||||||||||||||||||||||||||||||||
Non-GAAP adjusted | $ | 34,377 | $ | 25,892 | $ | 5,257 | $ | 2,737 | $ | 2,166 | $ | 26,439 | $ | (1,160 | ) | $ | — | $ | (11,620 | ) | $ | 67 | $ | (8,947 | ) |
Commercialization agreement revenues | Product Sales | Royalties and milestones | Cost of sales | Research and development expense | Selling, general and administrative expense | Restructuring Charges | Amortization of intangible assets | Interest expense | Other (Expense) Income, Net | Income taxes (expense) benefit | |||||||||||||||||||||||
GAAP as reported | 114,979 | 71,192 | 5,507 | 14,797 | 3,708 | 60,341 | 14,831 | 50,888 | (35,078 | ) | 296 | 445 | |||||||||||||||||||||
Commercialization agreement revenues and cost of sales | (49,288 | ) | — | (6,200 | ) | — | — | — | — | — | — | ||||||||||||||||||||||
NUCYNTA sales reserve | — | (10,711 | ) | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||
Non-cash interest expense on debt | — | — | — | — | — | — | — | — | 10,808 | — | — | ||||||||||||||||||||||
NUCYNTA and Lazanda revenue reserves | — | (1,166 | ) | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||
Expenses for opioid-related litigation, investigations and regulations | — | — | — | — | — | (3,047 | ) | — | — | — | — | — | |||||||||||||||||||||
Intangible amortization related to product acquisitions | — | — | — | — | — | — | (50,888 | ) | — | — | — | ||||||||||||||||||||||
Contingent consideration related to product acquisitions | — | — | — | — | — | 462 | — | — | — | — | — | ||||||||||||||||||||||
Stock based compensation | — | — | — | (30 | ) | (67 | ) | (4,849 | ) | — | — | — | — | — | |||||||||||||||||||
Restructuring and other costs | — | — | — | — | — | (178 | ) | (15,304 | ) | — | — | — | — | ||||||||||||||||||||
Income tax effect of non-GAAP adjustments | — | — | — | — | — | — | — | — | — | — | (5,623 | ) | |||||||||||||||||||||
Non-GAAP adjusted | 65,691 | 59,315 | 5,507 | 8,567 | 3,641 | 52,729 | (473 | ) | — | (24,270 | ) | 296 | (5,178 | ) |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2019 | 2018 | 2019 | 2018(1) | ||||||||||||
Total revenues (GAAP basis) | $ | 57.2 | $ | 63.3 | $ | 115.1 | $ | 191.7 | |||||||
Non-cash adjustment to commercialization agreement revenues(2) | 2.1 | 2.2 | 3.9 | (48.7 | ) | ||||||||||
Release of NUCYNTA sales reserves(3) | — | — | — | (12.5 | ) | ||||||||||
Total revenues (non-GAAP basis) | $ | 59.3 | $ | 65.5 | $ | 119.0 | $ | 130.5 |
Earnings (1) | ||||||||
Low End | High End | |||||||
GAAP | $ | (68 | ) | $ | (58 | ) | ||
Specified Items(2) | $ | 186 | $ | 186 | ||||
Non-GAAP | $ | 118 | $ | 128 |
Twelve Month Period | |||
Ended June 30, 2019 | |||
(unaudited) | |||
GAAP net (loss)/income | $ | (3,774 | ) |
Commercialization agreement revenues (1) | 27,987 | ||
Nucynta and Lazanda revenue reserves (2) | (384 | ) | |
Expenses for opioid-related litigation, investigations and regulations (3) | 9,700 | ||
Intangible amortization related to product acquisitions | 101,773 | ||
Contingent consideration related to product acquisitions | (195 | ) | |
Stock-based compensation | 10,829 | ||
Purdue Litigation | (62,000 | ) | |
Interest and other income | (1,706 | ) | |
Interest expense | 65,199 | ||
Depreciation | (382 | ) | |
Income taxes (expense) benefit | 2,863 | ||
Restructuring and related costs (4) | 5,965 | ||
Other costs | (55 | ) | |
Fair value for warrants | 3,477 | ||
Adjusted EBITDA | $ | 159,297 |